Vaccines 2013, 1(4), 527-549; doi:10.3390/vaccines1040527
Review

Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy

1 Department of Surgery and Harrison Department of Surgical Research, University of Pennsylvania, Philadelphia, PA 19104, USA 2 Rena Rowan Breast Center, University of Pennsylvania, Philadelphia, PA 19104, USA
* Author to whom correspondence should be addressed.
Received: 7 August 2013; in revised form: 18 October 2013 / Accepted: 7 November 2013 / Published: 21 November 2013
(This article belongs to the Special Issue Dendritic Cell Vaccine)
PDF Full-text Download PDF Full-Text [695 KB, uploaded 21 November 2013 16:29 CET]
Abstract: The success of cellular immunotherapies against cancer requires the generation of activated CD4+ and CD8+ T-cells. The type of T-cell response generated (e.g., Th1 or Th2) will determine the efficacy of the therapy, and it is generally assumed that a type-1 response is needed for optimal cancer treatment. IL-17 producing T-cells (Th17/Tc17) play an important role in autoimmune diseases, but their function in cancer is more controversial. While some studies have shown a pro-cancerous role for IL-17, other studies have shown an anti-tumor function. The induction of polarized T-cell responses can be regulated by dendritic cells (DCs). DCs are key regulators of the immune system with the ability to affect both innate and adaptive immune responses. These properties have led many researchers to study the use of ex vivo manipulated DCs for the treatment of various diseases, such as cancer and autoimmune diseases. While Th1/Tc1 cells are traditionally used for their potent anti-tumor responses, mounting evidence suggests Th17/Tc17 cells should be utilized by themselves or for the induction of optimal Th1 responses. It is therefore important to understand the factors involved in the induction of both type-1 and type-17 T-cell responses by DCs.
Keywords: dendritic cell vaccine; cancer; immunotherapy

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Terhune, J.; Berk, E.; Czerniecki, B.J. Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy. Vaccines 2013, 1, 527-549.

AMA Style

Terhune J, Berk E, Czerniecki BJ. Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy. Vaccines. 2013; 1(4):527-549.

Chicago/Turabian Style

Terhune, Julia; Berk, Erik; Czerniecki, Brian J. 2013. "Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy." Vaccines 1, no. 4: 527-549.

Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert